Skip to content

SGLT-2 Many Indications to Count: A Review of Cardiovascular and Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors

This activity is intended for ambulatory care pharmacists working as part of the health care team to develop treatment plans related to cardiovascular and renal disease.

SGLT2 inhibitors are FDA-approved for use in patients with type 2 diabetes. However, as with many medications, there are off-label uses for this class of medication. Within the last few years, there has been more and more data coming out regarding the cardiovascular and renal benefits of this class of medications.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Recall background information for SGLT2 inhibitors as a class, including mechanism of action, adverse effects, and labeled indications.
  • Discuss the recent evidence supporting the use of SGLT2 inhibitors for cardiovascular and renal benefits.
  • Explain how agents in this drug class may fit into the treatment algorithms in patients without diabetes.


Clare Cycz, PharmD is a current PGY1 pharmacy resident at Baystate Medical Center in Springfield, MA. She completed her Doctor of Pharmacy at the University of Connecticut in Storrs, CT (Go Huskies!). Her practice interests include critical care and emergency medicine.

Free to MCPHS Alumni and full-time employees; $12.00 for all other professionals.


ACPE logo

Release Date: June 1, 2021
Expiration Date: June 1, 2022
Contact Hours: 1 (.10 CEU)
Universal Activity Number: 0026-0000-21-130-H01-P | Knowledge-based
ACPE Topic Designator: Drug Therapy


Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this educational activity for a total of 1 contact hours (0.1 CEUs).

Requirements for Credit

In order to receive credit, the participant must view the entire presentation and complete the pre and post-test, and evaluation. Upon completion participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.

Statement of Disclosure

It is the policy of MCPHS-CE to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. All individuals engaged in the planning of a continuing education activity and who are in a position to control the educational content are required to disclose any financial relationships with ineligible companies occurring within the past 24 months. The intent of this policy is to identify and mitigate any potential conflict of interest that may directly or indirectly affect the activity. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

MCPHS will identify, review and mitigate all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

No funding from industry provided for this event. No exhibitors will be present.
Clare Cycz and MCPHS CE staff members hold no financial relationships with ineligible companies, related to the content of this presentation.